The purpose of this research study is to determine the safety, side effects, and effectiveness of a new formulation of melphalan when it is administered as part of the BEAM regimen, which is given prior to stem cell transplant. BEAM is a 4-drug chemotherapy combination using the following drugs: carmustine (also called BCNU), etoposide, cytarabine (also called Ara-C), and melphalan.